ImmunityBio Shares Face Pullback Amid Strong Operational Performance

After a multi-month rally, shares of biotechnology firm ImmunityBio are experiencing a notable correction. Investor sentiment has been dampened by an insider sale and the announcement of a legal investigation, even as the company reports record-breaking financial results and significant regulatory progress. The underlying fundamentals, however, paint a picture of a company accelerating its global footprint.

Regulatory Milestones and Financial Surge

On the operational front, ImmunityBio continues to deliver concrete achievements. The company recently submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration for its immunotherapy drug, ANKTIVA. This follows a request from the agency in February for updated efficacy data. The application is supported by long-term clinical trial results showing that over 58% of treated bladder cancer patients remained cancer-free after twelve months.

Financially, this progress is clearly reflected. Product revenue for ANKTIVA surged by approximately 700% in the past fiscal year 2025, reaching $113 million. Concurrently, the company’s net loss narrowed from $413.6 million to $351.4 million. With cash and equivalents of nearly $243 million, ImmunityBio appears well-funded for its next phase of development.

Investor Concerns: Profit-Taking and Legal Scrutiny

Despite gaining over 300% in value since the start of the year, the stock has retreated by about 19% in the past week. This recent pullback is primarily attributed to two developments. Director Barry J. Simon divested 175,000 shares worth close to $1.8 million in late February. Furthermore, the law firm Pomerantz announced it is investigating potential securities law violations. Such inquiries by specialized firms are not uncommon following significant stock movements in the biotech sector, though they often weigh on near-term market sentiment.

Should investors sell immediately? Or is it worth buying ImmunityBio?

International Growth and a Vision for the Future

Management is simultaneously advancing its international commercialization strategy. Having secured approvals in the United States, United Kingdom, and European Union, the company has recently established key distribution partnerships. An agreement with Accord Healthcare will leverage a sales force of 85 representatives across 30 European countries. In the Middle East, a market launch in Saudi Arabia is targeted within the next 60 days.

Additional long-term potential stems from the vision of founder Patrick Soon-Shiong. He aims to establish a global bank for natural killer (NK) cells. A project involving an AI-driven robot named Leonardo is intended to automate and scale future production, with the goal of delivering standardized cell therapies worldwide.

Market analysts view the operational trajectory positively. Piper Sandler raised its price target from $7 to $12 in early March, forecasting ANKTIVA revenue of $195 million for the current year. The next clear regulatory milestone is already on the calendar: ImmunityBio plans to submit another licensing application in the fourth quarter of 2026 for patients with early-stage bladder cancer, based on a recently completed study involving 366 participants.